Circumsporozoite-specific T cell responses in children vaccinated with RTS,S/AS01E and protection against P falciparum clinical malaria.

Circumsporozoite-specific T cell responses in children vaccinated with RTS,S/AS01E and protection against P falciparum clinical malaria.

BACKGROUND: RTS,S/AS01(E) is the lead candidate pre-erythrocytic malaria vaccine. In Phase IIb field trials the safety profile was acceptable and the efficacy was 53% (95%CI 31%-72%) for protecting children against clinical malaria caused by P. falciparum. We studied CS-specific T cell responses in...

Full description

Bibliographic Details
Main Authors:	Olotu, A, Moris, P, Mwacharo, J, Vekemans, J, Kimani, D, Janssens, M, Kai, O, Jongert, E, Lievens, M, Leach, A, Villafana, T, Savarese, B, Marsh, K, Cohen, J, Bejon, P
Format:	Journal article
Language:	English
Published:	2011

Similar Items

Circumsporozoite-specific T cell responses in children vaccinated with RTS,S/AS01E and protection against P falciparum clinical malaria.
by: Ally Olotu, et al.
Published: (2011-01-01)

A statistical interaction between circumsporozoite protein-specific T cell and antibody responses and risk of clinical malaria episodes following vaccination with RTS,S/AS01E
by: Ndungu, F, et al.
Published: (2012)

A statistical interaction between circumsporozoite protein-specific T cell and antibody responses and risk of clinical malaria episodes following vaccination with RTS,S/AS01E.
by: Francis M Ndungu, et al.
Published: (2012-01-01)

Avidity of anti-circumsporozoite antibodies following vaccination with RTS,S/AS01E in young children
by: Olotu, A, et al.
Published: (2014)

Avidity of anti-circumsporozoite antibodies following vaccination with RTS,S/AS01E in young children.
by: Ally Olotu, et al.
Published: (2014-01-01)

Efficacy of RTS,S/AS01E malaria vaccine and exploratory analysis on anti-circumsporozoite antibody titres and protection in children aged 5-17 months in Kenya and Tanzania: a randomised controlled trial.
by: Olotu, A, et al.
Published: (2011)

Efficacy of RTS,S/AS01E malaria vaccine and exploratory analysis on anti-circumsporozoite antibody titres and protection in children aged 5-17 months in Kenya and Tanzania: a randomised controlled trial
by: Olotu, A, et al.
Published: (2011)

Effect of the pre-erythrocytic candidate malaria vaccine RTS,S/AS01E on blood stage immunity in young children.
by: Bejon, P, et al.
Published: (2011)

Efficacy of RTS,S/AS01E vaccine against malaria in children 5 to 17 months of age.
by: Bejon, P, et al.
Published: (2008)

Four-year efficacy of RTS,S/AS01E and its interaction with malaria exposure.
by: Olotu, A, et al.
Published: (2013)

Induction of Plasmodium falciparum-specific CD4+ T cells and memory B cells in Gabonese children vaccinated with RTS,S/AS01(E) and RTS,S/AS02(D).
by: Selidji T Agnandji, et al.
Published: (2011-04-01)

Further analysis of correlates of protection from a phase 2a trial of the falciparum malaria vaccines RTS,S/AS01B and RTS,S/AS02A in malaria-naive adults.
by: Olotu, A, et al.
Published: (2010)

PHASE IIB, RANDOMIZED, DOUBLE-BLIND TRIAL TO ASSESS THE EFFICACY, SAFETY AND IMMUNOGENICITY OF THE CANDIDATE MALARIA VACCINE RTS,S/AS01 IN KENYAN AND TANZANIAN CHILDREN
by: Bejon, P, et al.
Published: (2008)

Safety of the malaria vaccine candidate, RTS,S/AS01E in 5 to 17 month old Kenyan and Tanzanian Children.
by: Lusingu, J, et al.
Published: (2010)

Antigen-specific IL-2 secretion correlates with NK cell responses after immunization of Tanzanian children with the RTS,S/AS01 malaria vaccine.
by: Horowitz, A, et al.
Published: (2012)

RTS,S/AS01E Vaccine against Malaria THE AUTHORS REPLY
by: Bejon, P, et al.
Published: (2009)

T cell responses to the RTS,S/AS01(E) and RTS,S/AS02(D) malaria candidate vaccines administered according to different schedules to Ghanaian children.
by: Daniel Ansong, et al.
Published: (2011-04-01)

Seven year efficacy of RTS,S/AS01 malaria vaccine in young African children
by: Olotu, A, et al.
Published: (2016)

Impact of RTS,S/AS02(A) and RTS,S/AS01(B) on genotypes of P. falciparum in adults participating in a malaria vaccine clinical trial.
by: John N Waitumbi, et al.
Published: (2009-11-01)

Correction: Safety of the Malaria Vaccine Candidate, RTS,S/AS01 in 5 to 17 Month Old Kenyan and Tanzanian Children.
by: John Lusingu, et al.
Published: (2010-01-01)

Safety of the malaria vaccine candidate, RTS,S/AS01E in 5 to 17 month old Kenyan and Tanzanian Children.
by: John Lusingu, et al.
Published: (2010-11-01)

Genetic variation in the Plasmodium falciparum circumsporozoite protein in India and its relevance to RTS,S malaria vaccine.
by: Mohammad Zeeshan, et al.
Published: (2012-01-01)

RTS,S malaria vaccine efficacy and immunogenicity during Plasmodium falciparum challenge is associated with HLA genotype
by: Nielsen, C, et al.
Published: (2018)

Statistical methodology for the evaluation of vaccine efficacy in a phase III multi-centre trial of the RTS, S/AS01 malaria vaccine in African children.
by: Lievens, M, et al.
Published: (2011)

A seven-year study on the effect of the pre-erythrocytic malaria vaccine candidate RTS,S/AS01E on blood stage immunity in young Kenyan children
by: Ndungu, F, et al.
Published: (2019)

Assessment of genetic diversity of Plasmodium falciparum circumsporozoite protein in Sudan: the RTS,S leading malaria vaccine candidate
by: Nouh Saad Mohamed, et al.
Published: (2021-11-01)

Humoral Immune Responses to P. falciparum Circumsporozoite Protein (Pfcsp) Induced by the RTS, S Vaccine – Current Update
by: Ngulube P
Published: (2023-04-01)

Statistical methodology for the evaluation of vaccine efficacy in a phase III multi-centre trial of the RTS,S/AS01 malaria vaccine in African children
by: Lievens Marc, et al.
Published: (2011-08-01)

A randomized trial assessing the safety and immunogenicity of AS01 and AS02 adjuvanted RTS,S malaria vaccine candidates in children in Gabon.
by: Bertrand Lell, et al.
Published: (2009-10-01)

Design of a phase III multicenter trial to evaluate the efficacy of the RTS,S/AS01 malaria vaccine in children across diverse transmission settings in Africa
by: Macete Eusebio, et al.
Published: (2011-08-01)

Seven-year kinetics of RTS, S/AS01-induced anti-CSP antibodies in young Kenyan children
by: Mugo, RM, et al.
Published: (2021)

Evaluation of RTS,S/AS02A and RTS,S/AS01B in adults in a high malaria transmission area.
by: Mark E Polhemus, et al.
Published: (2009-07-01)

Assessment of severe malaria in a multicenter, phase III, RTS, S/AS01 malaria candidate vaccine trial: case definition, standardization of data collection and patient care.
by: Vekemans, J, et al.
Published: (2011)

Serological evidence of discrete spatial clusters of Plasmodium falciparum parasites.
by: Bejon, P, et al.
Published: (2011)

Correction: Randomized Controlled Trial of RTS,S/AS02 and RTS,S/AS01 Malaria Candidate Vaccines Given According to Different Schedules in Ghanaian Children.
by: Seth Owusu-Agyei, et al.
Published: (2010-01-01)

Characterization of T-cell immune responses in clinical trials of the candidate RTS,S malaria vaccine
by: Philippe Moris, et al.
Published: (2018-01-01)

Randomized controlled trial of RTS,S/AS02D and RTS,S/AS01E malaria candidate vaccines given according to different schedules in Ghanaian children.
by: Seth Owusu-Agyei, et al.
Published: (2009-10-01)

Lack of avidity maturation of merozoite antigen-specific antibodies with increasing exposure to Plasmodium falciparum amongst children and adults exposed to endemic malaria in Kenya
by: Ibison, F, et al.
Published: (2012)

Environmental modifiers of RTS,S/AS01 malaria vaccine efficacy in Lilongwe, Malawi
by: Griffin J. Bell, et al.
Published: (2020-06-01)

Development of standardized laboratory methods and quality processes for a phase III study of the RTS, S/AS01 candidate malaria vaccine
by: Carter Terrell, et al.
Published: (2011-08-01)